BMRN Stock Recent News

Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2024 Results Conference Call August 5, 2024 5:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Hank Fuchs - President, Worldwide Research & Development Brian Mueller - Executive Vice President, Chief Financial Officer Cristin Hubbard - Executive Vice President, Chief Commercial Officer Conference Call Participants Phil Nadeau - TD Cowen Salveen Richter - Goldman Sachs Ellie Merle - UBS Cory Kasimov - Evercore Jessica Fye - JPMorgan Paul Matteis - Stifel Joseph Schwartz - Leerink Partners Chris Raymond - Piper Sandler Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Mohit Bansal - Wells Fargo Olivia Brayer - Cantor Fitzgerald Luca Issi - RBC Capital Operator Good afternoon, and welcome to the BioMarin Pharmaceuticals Second Quarter 2024 Conference Call. Please note that this call is being recorded.

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.54 per share a year ago.

Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 billion (+14% Y/Y and +19% at Constant Currency Y/Y) Second Quarter 2024 GAAP Diluted EPS of $0.55 (+90% Y/Y); First Half 2024 GAAP Diluted EPS of $1.01 (+80% Y/Y) Second Quarter 2024 Non-GAAP Diluted Earnings per Share (EPS) of $0.96 (+78% Y/Y); First Half 2024 Non-GAAP Diluted EPS of $1.67 (+46% Y/Y) Strong VOXZOGO® Demand in the Quarter Resulted in 73% Y/Y Increase in the Number of Children Receiving Treatment Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

Strategic Focus will Reduce Operating Expenses with the Goal of Achieving  ROCTAVIAN Profitability by End of 2025 BioMarin to Provide Continued Monitoring and Support to Those Treated in Clinical Trials and Commercially SAN RAFAEL, Calif. , Aug. 5, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced it will make changes to its ROCTAVIAN ® business to focus commercial operations on three markets, the United States, Germany and Italy, where the medicine is approved and reimbursed as a treatment for severe hemophilia A.

Evaluate the expected performance of BioMarin (BMRN) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, Calif. , July 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for BRINEURA® (cerliponase alfa) to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 5, 2024, at 4:30 p.m.